Mass tort lawsuit · Checked on November 3, 2026
Depo-Provera lawsuit: settlement status November 2026 (MDL 3140)
The Depo-Provera litigation is settling. The court's own order says a Master Settlement Agreement was signed on July 21, 2026, and that the parties estimate about 80% of MDL plaintiffs will be eligible. The terms are confidential. Plaintiffs allege the injectable contraceptive caused meningioma, a brain tumor. About 6,413 cases were pending on November 2, 2026.
| Case | MDL 3140 |
|---|---|
| Court | U.S. District Court, Northern District of Florida |
| Judge | M. Casey Rodgers |
| Pending cases | 6,413 (as of November 2, 2026) |
| Stage | Settlement signed July 2026 for eligible plaintiffs; terms confidential |
| New cases | Settlement in progress; check with a lawyer |
| Next scheduled date | November 30, 2026: settlement registration deadline (verified, Case Management Order No. 14). December 18, 2026: next court conference (verified, court orders page) |
| Last checked | November 3, 2026 |
What plaintiffs allege
Plaintiffs allege that Pfizer failed to warn that Depo-Provera (medroxyprogesterone acetate injections) increases the risk of intracranial meningioma. Pfizer has disputed the claims.
Where the case stands
- June 15, 2026: plaintiffs' leadership announced a settlement of a majority of the claims in the MDL and New York state court (verified, Case Management Order No. 12).
- July 21, 2026: the parties signed a Master Settlement Agreement; its eligibility terms decide who can take part (verified, same order).
- A later order, Case Management Order No. 14 (August 10, 2026), dates the agreement July 22, 2026 (verified).
- The court canceled the December 2026 pilot trial and noted that new cases continued to be filed "at a greatly reduced rate" (verified, same order).
- The court held the hearing on general causation for people outside the settlement on September 18, 2026; no ruling had been reported as of November 3, 2026 (reported).
- The court set November 30, 2026 as the deadline to register for the settlement program (verified, Case Management Order No. 14).
- In December 2025 the FDA approved a label change adding meningioma information for both Depo-Provera injections (verified, FDA approval letter; month reported).
Settlement status
A Master Settlement Agreement for eligible plaintiffs was signed on July 21, 2026, and the parties estimate that about 80% of MDL plaintiffs will be eligible (verified, Case Management Order No. 12). The terms, including amounts, are confidential, and we do not estimate payments.
Updates
Newest first. Each entry says whether we read the record ourselves (verified) or it comes from coverage (reported).
- November 2026: The federal panel's report of November 2, 2026 listed 6,413 pending cases (verified, JPML report).
- October 2026: The federal panel's report of October 1, 2026 listed 6,412 pending cases (verified, JPML report).
- September 2026: The court held the general causation hearing for people outside the settlement on September 18; a ruling is pending (reported).
- August 2026: Case Management Order No. 14 set November 30, 2026 as the settlement registration deadline (verified).
- July 2026: The parties signed a Master Settlement Agreement on July 21. On July 27 the court canceled the December 2026 pilot trial (verified, Case Management Order No. 12).
- June 2026: Plaintiffs' leadership announced a settlement of a majority of the claims on June 15 (verified, Case Management Order No. 12).
- December 2025: The FDA approved a label change adding meningioma information (verified, FDA approval letter; month reported).
What law firms commonly ask callers
Law firms reviewing these cases usually ask about the following. This is general information, not an assessment of any claim:
- how long Depo-Provera injections were used
- whether an MRI or pathology confirmed meningioma
- the diagnosis date
Questions
Is the Depo-Provera lawsuit real?
Yes. The U.S. Judicial Panel on Multidistrict Litigation listed 6,413 pending cases in MDL 3140 as of November 2, 2026 (verified). A pending case is a claim filed in court, not a finding that the claim is true.
When will the Depo-Provera lawsuit settle?
Nobody can predict when or whether a mass tort will settle. What has been disclosed so far: A Master Settlement Agreement for eligible plaintiffs was signed on July 21, 2026, and the parties estimate that about 80% of MDL plaintiffs will be eligible (verified, Case Management Order No. 12). The terms, including amounts, are confidential, and we do not estimate payments.
Can Depo-Provera cause brain tumors?
In December 2025 the FDA approved a label change adding meningioma information (verified, FDA approval letter). Whether Depo-Provera caused a particular person's tumor is what the lawsuits dispute. For medical questions, talk to your doctor.
How much is the Depo-Provera settlement per person?
The terms are confidential and have not been published by the court. We do not estimate amounts.
Can new people still join?
That depends on the settlement's confidential eligibility terms. The court has stated that the deadline to register for the settlement program is November 30, 2026 (verified, Case Management Order No. 14). Only a lawyer reviewing the program can say whether it applies to a person.
Sources
- JPML, Pending MDL Dockets by Actions Pending, November 2, 2026 verified
- N.D. Fla., Case Management Order No. 12 (July 27, 2026) verified
- N.D. Fla., Case Management Order No. 14 (August 10, 2026) verified
- N.D. Fla., MDL 3140 orders by date verified
- FDA approval letter, NDA 020246/S-074 and NDA 021583/S-045 (meningioma labeling) verified
- NBC News on the FDA label change reported
Verified means we read the court, agency or company record ourselves on the check date. Reported means the fact comes from news or law firm coverage and could not be confirmed on a primary record.